menu
    • menu
    [{"orgOrder":0,"company":"Nora Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Nora Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nora Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nora Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nora Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bilastine","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Nora Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nora Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nora Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nora Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Lurasidone Hydrochloride","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Nora Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nora Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nora Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nora Pharma","sponsor":"Nora Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Prucalopride Succinate","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Nora Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Nora Pharma \/ Nora Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Nora Pharma \/ Nora Pharma"},{"orgOrder":0,"company":"Nora Pharma","sponsor":"Sunshine Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Pravastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Nora Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nora Pharma \/ Sunshine Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Nora Pharma \/ Sunshine Biopharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Nora Pharma

    Menu

    Nora Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nora Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Nora Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pravastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Sunshine Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sunshine Biopharma Launches Cholesterol-Fighting Pravastatin Medicine

                            Details : Pravastatin Sodium, a miscellaneous product targeting HMG-CoA reductase, shows promise in treating high cholesterol.

                            Product Name : Pravachol-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 16, 2025

                            Lead Product(s) : Pravastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Sunshine Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nora Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Nora Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lurasidone Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in Canada

                            Details : Lurasidone HCl is a D2 and 5HT2A inhibitor, indicated for the management of schizophrenia and bipolar depression.

                            Product Name : Latuda-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 06, 2025

                            Lead Product(s) : Lurasidone Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nora Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Nora Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Prucalopride Succinate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Recipient : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sunshine Biopharma to Launch Two GI Drugs in $200M Canadian Market

                            Details : Nora Pharma has acquired the rights to two gastrointestinal drugs, which includes Motegrity-Generic (prucalopride succinate). It is indicated for the treatment of chronic idiopathic constipation.

                            Product Name : Motegrity-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 10, 2025

                            Lead Product(s) : Prucalopride Succinate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Recipient : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nora Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Nora Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sunshine Biopharma Launches a New Generic Prescription Drug

                            Details : Blexten-Generic (bilastine) is a histamine H1 receptor inhibitor, which is indicated for the treatment of seasonal allergic rhinitis & chronic spontaneous urticaria.

                            Product Name : Blexten-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 05, 2024

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nora Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Nora Pharma

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegfilgrastim

                            Therapeutic Area : Hematology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sunshine Biopharma's Nora Pharma Receives Approval for Niopeg(R) Biosimilar

                            Details : Niopeg (pegfilgrastim) is an FDA-approved G-CSF agonist for treating febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy.

                            Product Name : Niopeg

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            April 19, 2024

                            Lead Product(s) : Pegfilgrastim

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth